PRESS RELEASE 2024

Parsippany, NJ – November 13, 2024 – Ferring Pharmaceuticals is grateful  to New Jersey and Minnesota for recognizing November as Clostridioides difficile (C. diff) Infection Awareness Month. This is the fifth year in a row that the offices of Governor Phil Murphy (New Jersey) and Governor Tim Wa...

Real-world analyses evaluated the effectiveness of REBYOTA in patients with GI conditions or comorbidities as well as those who received therapy at home or in a clinic Interim data from a third analysis reported on changes in health-related quality of life  among REBYOTA patients Analyses add to ...

Four abstracts, including two oral and two poster presentations, highlight Ferring’s dedication and multi-focus approach to advancing fertility care Parsippany, NJ – October 18, 2024 – Ferring Pharmaceuticals will present new data from four abstracts at the upcoming 2024 American Society fo...

New outcomes analyses evaluated efficacy and safety of REBYOTA in patients with recurrent C. diff infection in a real-world setting Patients were followed after receiving REBYOTA at home or in a clinic Findings add to the growing body of real-world evidence for REBYOTA Parsippany, NJ – October 16...

Parsippany, NJ – September 9, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced they will be presenting an analysis of data at the North American Spine Society’s (NASS) Annual Meeting from two Phase 3 trials for SI-6603, an inv...

A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 with notable differences observed as early as Week 4 No treatment-related serious adverse events occurred with SI-6603 Additional analysis presented at ASPN evaluated economic ...

Parsippany, NJ – June 24, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of two analyses of data at the American Society of Pain and Neuroscience (ASPN) 2024 Annual Meeting, for SI-6603, an investigational t...

1 in 6 people worldwide experience infertility and up to 50% of the time there is a contributing male factor.1,2,3 Stigma, lack of awareness and longer-lead times for the initial male fertility evaluation may impact a couple’s path to parenthood.                                            […]

First real-world outcomes analysis evaluated efficacy of REBYOTA in patients with recurrent C. diff infection Ad-hoc analysis evaluated efficacy and safety of REBYOTA in participants taking common non-antibiotic medications associated with microbiome imbalance and recurrent C. diff infection Post...

SI-6603 is an investigational therapy intended to treat radicular leg pain associated with lumbar disc herniation Lumbar disc herniation can cause severe, debilitating pain Parsippany, NJ – May 14, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikaga...

Final analysis shows ADSTILADRIN was well-tolerated with no new study drug-related adverse events — <4% of patients experienced Grade 3 AEs, there were no Grade 4 or 5 AEs — and no new safety signals reported In the overall study population at Month 60, the Kaplan-Meier (KM) estimated overall ...

Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal assures diversity of supply to meet future long-term plans for expanded availability of the gene therapy Two additional...

Expanded clinical trial program with ADSTILADRIN starts up in the United States Current clinical trial program of five multi-year studies to evaluate ADSTILADRIN demonstrate Ferring’s commitment to improve outcomes for patients across the spectrum of urothelial cancers Research will enlarge the b...

A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in a registrational Phase 3 clinical trial An integrated safety analysis showed SI-6603 was well tolerated and could offer a potential treatment option for pain relief from Lum...

Results of a Phase 3 study show durable complete response in evaluation of high-grade recurrence-free survival, cystectomy-free survival, and overall survival in patients with CIS ± Ta/T1 (primary analysis) and high-grade Ta/T1 without CIS (secondary analysis) Among the 53% of patients with BCG-u...

Ferring presenting design and methodology for the ABLE-41 Real-World Evidence study at this week’s 20th Annual ASCO Genitourinary Cancers Symposium in San Francisco Study evaluating effectiveness, overall experiences, patterns of use, and safety of the first and only FDA-approved intravesical gen...

Patients with high-risk, non-muscle invasive bladder cancer now have greater access to the first and only FDA-approved intravesical gene therapy With full supply of ADSTILADRIN ahead of schedule, Ferring ends the temporary ADSTILADRIN Early Experience Program Enrollment in ABLE-41 U.S. Real-World...